Form 4: Xenon Pharmaceuticals Inc. Executive Christopher John Kenney Reports Acquisition of Share Options and Restricted Share Units

Chief Medical Officer Christopher John Kenney reports acquisition of share options and restricted share units in Xenon Pharmaceuticals Inc.

Summary

• On March 12, 2025, Christopher John Kenney, Chief Medical Officer of Xenon Pharmaceuticals Inc., reported the acquisition of 80,000 share options and 15,000 restricted share units.
• The share options have an exercise price of $35.48 and vest 25% on March 12, 2026, with the remaining 75% vesting over the following three years in equal monthly installments.
• The restricted share units vest 25% on each of the first four anniversaries of the grant date, starting March 12, 2026.
• Following these transactions, Kenney directly owns 80,000 share options and 15,000 restricted share units.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The acquisition of share options and restricted share units by a key executive generally indicates confidence in the company's future prospects, but it's a routine filing.

Positives

• The acquisition of share options and restricted share units by a key executive signals confidence in the company's future performance.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules suggest a multi-year commitment from the executive.

Industry Context

Form 4 filings are standard practice and provide transparency into executive compensation and ownership, which is important for investor confidence in the pharmaceutical industry.

Comparison to Industry Standards

• Executive compensation packages including share options and restricted share units are common in the pharmaceutical industry to align management interests with shareholder value.
• Companies like Amgen, Biogen, and Vertex Pharmaceuticals also utilize similar equity-based compensation strategies.
• The vesting schedules are typical, designed to incentivize long-term performance and retention.

Stakeholder Impact

• Shareholders may view the executive's increased stake in the company positively.
• Employees may see this as a sign of stability and growth potential.

Key Dates